PT - JOURNAL ARTICLE AU - Li, Minjie AU - Yang, Juan AU - Wang, Lin AU - Wu, Qianhui AU - Wu, Zhiwei AU - Zheng, Wen AU - Wang, Lei AU - Lu, Wanying AU - Deng, Xiaowei AU - Peng, Cheng AU - Han, Bihua AU - Zhao, Yuliang AU - Yu, Hongjie AU - Yin, Weidong TI - A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial AID - 10.1101/2021.08.03.21261544 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.03.21261544 4099 - http://medrxiv.org/content/early/2021/08/08/2021.08.03.21261544.short 4100 - http://medrxiv.org/content/early/2021/08/08/2021.08.03.21261544.full AB - Importance Whether herd immunity through mass vaccination is sufficient to curb SARS-CoV-2 transmission requires an understanding of the duration of vaccine-induced immunity, and the necessity and timing of booster doses. Objective: To evaluate immune persistence of two priming doses of CoronaVac, and immunogenicity and safety of a third dose in healthy adults ≥60 years. Design, setting, and participants: We conducted a vaccine booster study built on a single-center, randomized, double-blind phase 1/2 trial of the two-dose schedule of CoronaVac among healthy adults≥60 years in Hebei, China. We examined neutralizing antibody titres six months or more after the second dose in all participants. We provided a third dose to 303 participants recruited in phase 2 trial to assess their immune responses.Interventions Two formulations (3 μg, and 6 μg) were used in phase 1 trial, and an additional formulation of 1.5 μg was used in phase 2 trial. All participants were given two doses 28 days apart and followed up 6 months after the second dose. Participants in phase 2 received a third dose 8 months after the second dose.Main outcomes and measures Geometric mean titres (GMT) of neutralizing antibodies to live SARS-CoV-2 and adverse events were assessed at multiple time points following vaccination.Results Neutralizing antibody titres dropped below the seropositive cutoff of 8 at 6 months after the primary vaccination in all vaccine groups in the phase 1/2 trial. A third dose given 8 months or more after the second dose significantly increased neutralizing antibody levels. In the 3 μg group (the licensed formulation), GMT increased to 305 [95%CI 215.3-432.0] on day 7 following the third dose, an approximately 7-fold increase compared with the GMT 28 days after the second dose. All solicited adverse reactions reported within 28 days after a booster dose were of grade 1 or 2 severity.Conclusion and relevance Neutralizing antibody titres declined substantially six months after two doses of CoronaVac among older adults. A booster dose rapidly induces robust immune responses. This evidence could help policymakers determine the necessity and the timing of a booster dose for older adults.Trial registration ClinicalTrials.gov (NCT04383574).Competing Interest StatementH.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. None of those research funding is related to development of COVID-19 vaccines. L.W. and Y.W. were the employees of Sinovac Biotech Ltd., L.W. was an employee of Sinovac Life Sciences Co., Ltd. All other authors report no competing interests.Clinical TrialClinicalTrials.gov (NCT04383574)Funding StatementThe study was supported by grants from National Key Research and Development Program (2020YFC0849600), Beijing Science and Technology Program (Z201100005420023), and National Science Fund for Distinguished Young Scholars (81525023).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from each participant before the third dose in the second part of the study. The clinical trial protocol and informed consent form were approved by the Ethics Committee of Hebei CDC (IRB2020-006).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data referred to in the manuscript will be provided with reasonable request after the trial is completed.